Abstract
Dear Drs. Goldenberg and Sharkey,Thank you for the letter regarding our MCT article. The goal of our publication was to disclose our latest camptothecin research in a context of relevant drug-linkers from clinically validated technologies. Our findings with GT, the drug component within the clinically approved drug Trodelvy developed in your lab were generally consistent with your publication (reference 30) indicating that instability led to free drug release. We appreciate your comments that altered in vitro assay conditions can be used to improve specificity. Our goal was to highlight preclinical distinctions between our new technology and those within Trodelvy and Enhertu, ADCs that were cited throughout our article. The comparisons were not intended to be comprehensive, but the specificity profile and pronounced in vivo activities in our publication bode well for the technology platform we present. We agree that the ultimate value of new drug-linker technologies will require extensive clinical investigation.See the original Letter to the Editor, p. 237No disclosures were reported.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
